Information Provided By: 
Fly News Breaks for March 29, 2017
REGN
Mar 29, 2017 | 06:42 EDT
Citi analyst Robyn Karnauskas believes Regeneron Pharmaceuticals is taking a smart approach to the Dupixent launch by going after the sickest moderate to severe atopic dermatitis patients. A lack of payer pushback, which is the biggest investor concern, could make the launch look better than the street expectations of $138M for 2017, Karnauskas tells investors in a research note. She keeps a Buy rating on Regeneron with a $420 price target.
News For REGN From the Last 2 Days
